查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1790481

美國抗生素抗藥性市場規模、佔有率及趨勢分析報告：按疾病、病原體、藥物類別、作用機制、通路和細分市場預測，2025-2030 年

U.S. Antibiotic Resistance Market Size, Share, & Trends Analysis Report By Disease (cUTI, CDI), By Pathogen, By Drug Class, By Mechanism of Action, By Distribution Channel, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格

美國抗生素抗藥性市場摘要

美國抗生素抗藥性市場規模預計在 2024 年將達到 30.9 億美元，預計到 2030 年將達到 39.9 億美元，2025 年至 2030 年的複合年成長率為 4.4%。預計市場成長將受到抗生素濫用和過度使用增加的推動。

根據美國疾病管制與預防中心統計，美國每年報告的抗生素抗藥性感染疾病超過 280 萬例，導致 35,000 人死亡。此外，日益成長的公共衛生問題和對新型抗生素療法的需求預計將推動市場成長。據世界衛生組織稱，動物、人類和植物中抗生素的過度使用和濫用是導致抗藥性病原體產生的主要原因。抗生素抗藥性使感染疾病更難治療，包括癌症化療和置換術的醫療方法也更具風險。抗生素抗藥性市場正在經歷強勁成長，這得益於對能夠對抗細菌對現有藥物日益成長的抗藥性的治療方法的迫切需求。

當您感染疾病抗生素抗藥性細菌時，病情會變得更加難以控制，因為目前有效治療感染疾病的抗生素種類越來越少。此外，這些抗藥性細菌也會傳播給其他人，增加感染擴散的風險。在極少數情況下，可用的治療方案可能非常有限。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國抗生素抗藥性市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析

第4章美國抗生素抗藥性市場分析工具

  • 產業分析-波特五力分析
    • 供應商權力
    • 購買力
    • 替代威脅
    • 新進入者的威脅
    • 競爭對手之間的競爭
  • PESTEL分析
    • 政局
    • 技術格局
    • 經濟情勢
  • 美國抗生素抗藥性市場：管道分析

第5章美國抗生素抗藥性市場：疾病估計與趨勢分析

  • 疾病細分儀表板
  • 美國抗生素抗藥性市場：疾病趨勢分析
  • 美國抗生素抗藥性市場規模與趨勢分析（按疾病，2018-2030 年）
  • CUTI
  • CDI
  • ABSSSI
  • HABP
  • CABP
  • cIAI
  • BSI

第6章美國抗生素抗藥性市場：病原體估計和趨勢分析

  • 病原體細分儀表板
  • 美國抗生素抗藥性市場：病原體變異分析
  • 美國抗生素抗藥性市場規模及趨勢分析（按病原體，2018-2030）
  • 大腸桿菌
  • 肺炎克雷伯菌
  • 銅綠假單胞菌
  • 金黃色葡萄球菌
  • A. 鮑曼
  • 肺炎球菌
  • 流感細菌
  • CDI
  • 屎腸球菌

第7章美國抗生素抗藥性市場：藥物類別估計與趨勢分析

  • 藥品類別細分儀表板
  • 美國抗生素抗藥性市場：藥物類別變異分析
  • 美國抗生素抗藥性市場規模及趨勢分析（依藥物類別，2018-2030）
  • Oxazolidinone
  • 醣肽
  • 四環黴素
  • 聯合治療
  • 頭孢菌素類
  • 其他

第8章美國抗生素抗藥性市場：作用機制評估與趨勢分析

  • 作用機制細分儀表板
  • 美國抗生素抗藥性市場：作用機制變異分析
  • 美國抗生素抗藥性市場規模及趨勢分析（按作用機制，2018-2030）
  • 蛋白質合成抑制劑
  • 細胞壁合成抑制劑
  • RNA合成抑制劑
  • DNA合成抑制劑
  • 其他

第9章美國抗生素抗藥性市場：通路評估與趨勢分析

  • 分銷通路細分儀表板
  • 美國抗生素抗藥性市場：分佈波動分析
  • 美國抗生素抗藥性市場規模及通路趨勢分析（2018-2030）
  • 零售藥局
  • 醫院藥房
  • 網路藥局

第10章 競爭格局

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • Key company heat map analysis, 2024
  • 公司簡介
    • Melinta Therapeutics
    • Merck &Co., Inc.
    • Melinta Therapeutics LLC
    • Theravance Biopharma.
    • Paratek Pharmaceuticals, Inc.
    • Seres Therapeutics
    • AbbVie Inc.
Product Code: GVR-4-68040-664-4

U.S. Antibiotic Resistance Market Summary

The U.S. antibiotic esistance market size was estimated at USD 3.09 billion in 2024 and is projected to reach USD 3.99 billion by 2030, growing at a CAGR of 4.4% from 2025 to 2030. The market is expected to grow, driven by the rising misuse and overuse of antibiotics.

According to the CDC, more than 2.8 million antimicrobial-resistant infections are reported every year in the U.S., leading to 35,000 deaths. Moreover, the rise of public health concerns and the need for new antibiotic therapies are expected to drive market growth. According to the WHO, the overuse and misuse of antibiotics in animals, humans, and plants are the main reasons for the development of drug-resistant pathogens. Antibiotic resistance makes infections hard to treat and makes medical treatments, including cancer chemotherapy and surgeries such as cesarean sections and hip replacements, riskier. The market for antibiotic therapies is witnessing strong growth, driven by the urgent demand for treatments that can counteract rising resistance to existing drugs.

When a person contracts an infection caused by antibiotic-resistant bacteria, managing the illness becomes more challenging because fewer antibiotics can effectively treat the infection. In addition, these resistant bacteria can be transmitted to others, increasing the risk of wider spread. There are some rare instances where very few treatment options may be available.

U.S. Antibiotic Resistance Market Report Segmentation

This report forecasts revenue at the country level and analyzes the latest industry trends in each sub-segment from 2018 to 2030. For this study, Grand View Research has segmented the U.S. Antibiotic Resistance Market report based on disease, pathogen, drug class, mechanism of action, and distribution channel:

  • Disease Outlook (Revenue in USD Million, 2018 - 2030)
  • cUTI
  • CDI
  • ABSSSI
  • HABP
  • CABP
  • cIAI
  • BSI
  • Pathogen Outlook (Revenue in USD Million, 2018 - 2030)
  • E. coli
  • klebsiella pneumoniae
  • P. aeruginosa
  • S. aureus
  • baumannii
  • Strep. Pneumoniae
  • H. influenzae
  • CDI
  • Enterococcus fecium
  • Drug Class Outlook (Revenue in USD Million; 2018 - 2030)
  • Oxazolidinones
  • Lipoglycopeptides
  • Tetracyclines
  • Combination therapies
  • Cephalosporins
  • Others
  • Mechanism of Action Outlook (Revenue in USD Million; 2018 - 2030)
  • Protein Synthesis Inhibitors
  • Cell Wall Synthesis Inhibitors
  • RNA Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • Others
  • Distribution Channel Outlook (Revenue in USD Million; 2018 - 2030)
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Pathogen
    • 1.2.3. Drug Class
    • 1.2.4. Mechanism of Action
    • 1.2.5. Distribution Channel
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Disease outlook
    • 2.2.2. Pathogen outlook
    • 2.2.3. Drug Class outlook
    • 2.2.4. Mechanism of Action
    • 2.2.5. Distribution Channel
  • 2.3. Competitive Insights

Chapter 3. U.S. Antibiotic Resistance Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis

Chapter 4. U.S. Antibiotic Resistance Market Analysis Tools

  • 4.1. Industry Analysis - Porter's
    • 4.1.1. Supplier power
    • 4.1.2. Buyer power
    • 4.1.3. Substitution threat
    • 4.1.4. Threat of new entrant
    • 4.1.5. Competitive rivalry
  • 4.2. PESTEL Analysis
    • 4.2.1. Political landscape
    • 4.2.2. Technological landscape
    • 4.2.3. Economic landscape
  • 4.3. U.S. Antibiotic Resistance Market: Pipeline Analysis

Chapter 5. U.S. Antibiotic Resistance Market: Disease Estimates & Trend Analysis

  • 5.1. Disease Segment Dashboard
  • 5.2. U.S. Antibiotic Resistance Market: Disease Movement Analysis
  • 5.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Disease, 2018 to 2030 (USD Million)
  • 5.4. cUTI
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. CDI
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. ABSSSI
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. HABP
    • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. CABP
    • 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. cIAI
    • 5.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.10. BSI
    • 5.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Antibiotic Resistance Market: Pathogen Estimates & Trend Analysis

  • 6.1. Pathogen Segment Dashboard
  • 6.2. U.S. Antibiotic Resistance Market: Pathogen Movement Analysis
  • 6.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Pathogen, 2018 to 2030 (USD Million)
  • 6.4. E. coli
    • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. klebsiella pneumoniae
    • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. P. aeruginosa
    • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. S. aureus
    • 6.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. A. baumannii
    • 6.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. Strep. Pneumoniae
    • 6.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.10. H. influenzae
    • 6.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.11. CDI
    • 6.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.12. Enterococcus fecium
    • 6.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Antibiotic Resistance Market: Drug Class Estimates & Trend Analysis

  • 7.1. Drug Class Segment Dashboard
  • 7.2. U.S. Antibiotic Resistance Market: Drug Class Movement Analysis
  • 7.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 7.4. Oxazolidinones
    • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 7.5. Lipoglycopeptides
    • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Tetracyclines
    • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Combination therapies
    • 7.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Cephalosporins
    • 7.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. Others
    • 7.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. U.S. Antibiotic Resistance Market: Mechanism of Action Estimates & Trend Analysis

  • 8.1. Mechanism of Action Segment Dashboard
  • 8.2. U.S. Antibiotic Resistance Market: Mechanism of Action Movement Analysis
  • 8.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Mechanism of Action, 2018 to 2030 (USD Million)
  • 8.4. Protein Synthesis Inhibitors
    • 8.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 8.5. Cell Wall Synthesis Inhibitors
    • 8.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. RNA Synthesis Inhibitors
    • 8.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. DNA Synthesis Inhibitors
    • 8.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Others
    • 8.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. U.S. Antibiotic Resistance Market: Distribution Channel Estimates & Trend Analysis

  • 9.1. Distribution Channel Segment Dashboard
  • 9.2. U.S. Antibiotic Resistance Market: Distribution Movement Analysis
  • 9.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 9.4. Retail Pharmacies
    • 9.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 9.5. Hospital Pharmacies
    • 9.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6. Online Pharmacies
    • 9.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 10.2. Company/Competition Categorization
  • 10.3. Vendor Landscape
    • 10.3.1. Key company heat map analysis, 2024
  • 10.4. Company Profiles
    • 10.4.1. Melinta Therapeutics
      • 10.4.1.1. Company overview
      • 10.4.1.2. Financial performance
      • 10.4.1.3. Product benchmarking
      • 10.4.1.4. Strategic initiatives
    • 10.4.2. Merck & Co., Inc.
      • 10.4.2.1. Company overview
      • 10.4.2.2. Financial performance
      • 10.4.2.3. Product benchmarking
      • 10.4.2.4. Strategic initiatives
    • 10.4.3. Melinta Therapeutics LLC
      • 10.4.3.1. Company overview
      • 10.4.3.2. Financial performance
      • 10.4.3.3. Product benchmarking
      • 10.4.3.4. Strategic initiatives
    • 10.4.4. Theravance Biopharma.
      • 10.4.4.1. Company overview
      • 10.4.4.2. Financial performance
      • 10.4.4.3. Product benchmarking
      • 10.4.4.4. Strategic initiatives
    • 10.4.5. Paratek Pharmaceuticals, Inc.
      • 10.4.5.1. Company overview
      • 10.4.5.2. Financial performance
      • 10.4.5.3. Product benchmarking
      • 10.4.5.4. Strategic initiatives
    • 10.4.6. Seres Therapeutics
      • 10.4.6.1. Company overview
      • 10.4.6.2. Financial performance
      • 10.4.6.3. Product benchmarking
      • 10.4.6.4. Strategic initiatives
    • 10.4.7. AbbVie Inc.
      • 10.4.7.1. Company overview
      • 10.4.7.2. Financial performance
      • 10.4.7.3. Product benchmarking
      • 10.4.7.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 U.S. Antibiotic Resistance market, by Disease, 2018 - 2030 (USD Million)
  • Table 3 U.S. Antibiotic Resistance market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 4 U.S. Antibiotic Resistance market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 5 U.S. Antibiotic Resistance market, by Mechanism of Action, 2018 - 2030 (USD Million)
  • Table 6 U.S. Antibiotic Resistance market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. antibiotic resistance market: market outlook
  • Fig. 10 U.S. antibiotic resistance competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. antibiotic resistance market driver impact
  • Fig. 16 U.S. antibiotic resistance market restraint impact
  • Fig. 17 U.S. antibiotic resistance market strategic initiatives analysis
  • Fig. 18 U.S. antibiotic resistance market: Disease movement analysis
  • Fig. 19 U.S. antibiotic resistance market: Disease outlook and key takeaways
  • Fig. 20 cUTI market estimates and forecast, 2018 - 2030
  • Fig. 21 CDI estimates and forecast, 2018 - 2030
  • Fig. 22 ABSSSI market estimates and forecast, 2018 - 2030
  • Fig. 23 HABP market estimates and forecast, 2018 - 2030
  • Fig. 24 CABP market estimates and forecast, 2018 - 2030
  • Fig. 25 cIAI estimates and forecast, 2018 - 2030
  • Fig. 26 BSI estimates and forecast, 2018 - 2030
  • Fig. 27 U.S. antibiotic resistance market: Pathogen movement analysis
  • Fig. 28 U.S. antibiotic resistance market: Pathogen outlook and key takeaways
  • Fig. 29 E. coli market estimates and forecasts, 2018 - 2030
  • Fig. 30 klebsiella pneumoniae market estimates and forecasts, 2018 - 2030
  • Fig. 31 P. aeruginosa market estimates and forecasts, 2018 - 2030
  • Fig. 32 S. aureus market estimates and forecasts, 2018 - 2030
  • Fig. 33 A. baumannii market estimates and forecasts, 2018 - 2030
  • Fig. 34 Strep. Pneumoniae market estimates and forecasts, 2018 - 2030
  • Fig. 35 H. influenzae market estimates and forecasts, 2018 - 2030
  • Fig. 36 CDI market estimates and forecasts, 2018 - 2030
  • Fig. 37 Enterococcus fecium market estimates and forecasts, 2018 - 2030
  • Fig. 38 U.S. antibiotic resistance market: Drug class movement analysis
  • Fig. 39 U.S. antibiotic resistance market: Drug class outlook and key takeaways
  • Fig. 40 Oxazolidinones market estimates and forecasts, 2018 - 2030
  • Fig. 41 Lipoglycopeptides market estimates and forecasts, 2018 - 2030
  • Fig. 42 Tetracyclines market estimates and forecasts, 2018 - 2030
  • Fig. 43 Combination therapies market estimates and forecasts, 2018 - 2030
  • Fig. 44 Cephalosporins market estimates and forecasts, 2018 - 2030
  • Fig. 45 Others market estimates and forecasts, 2018 - 2030
  • Fig. 46 U.S. antibiotic resistance market: Mechanism of action movement analysis
  • Fig. 47 U.S. antibiotic resistance market: Mechanism of action outlook and key takeaways
  • Fig. 48 Protein synthesis inhibitors market estimates and forecasts, 2018 - 2030
  • Fig. 49 Cell wall synthesis inhibitors market estimates and forecasts, 2018 - 2030
  • Fig. 50 RNA synthesis inhibitors market estimates and forecasts, 2018 - 2030
  • Fig. 51 DNA synthesis inhibitors market estimates and forecasts, 2018 - 2030
  • Fig. 52 Others market estimates and forecasts, 2018 - 2030
  • Fig. 53 U.S. antibiotic resistance market: Distribution channel movement analysis
  • Fig. 54 U.S. antibiotic resistance market: Distribution channel outlook and key takeaways
  • Fig. 55 Retail pharmacies market estimates and forecasts, 2018 - 2030
  • Fig. 56 Hospital pharmacies market estimates and forecasts, 2018 - 2030
  • Fig. 57 Online pharmacies market estimates and forecasts, 2018 - 2030